Aliskiren Hemifumarate; Amlodipine Besylate Patent Expiration

Aliskiren Hemifumarate; Amlodipine Besylate is Used for treating high blood pressure. It was first introduced by Novartis Pharmaceuticals Corp in its drug Tekamlo on Aug 26, 2010.


Aliskiren Hemifumarate; Amlodipine Besylate Patents

Given below is the list of patents protecting Aliskiren Hemifumarate; Amlodipine Besylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tekamlo US8613949 Galenical formulations of organic compounds Dec 21, 2029 Novartis
Tekamlo US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides Jul 21, 2018

(Expired)

Novartis



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aliskiren Hemifumarate; Amlodipine Besylate's patents.

Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate; Amlodipine Besylate.

Activity Date Patent Number
Patent litigations
Expire Patent 31 Jan, 2022 US8613949
Maintenance Fee Reminder Mailed 16 Aug, 2021 US8613949
Patent Issue Date Used in PTA Calculation 24 Dec, 2013 US8613949
Recordation of Patent Grant Mailed 24 Dec, 2013 US8613949
Email Notification 05 Dec, 2013 US8613949
Issue Notification Mailed 04 Dec, 2013 US8613949
Application Is Considered Ready for Issue 22 Nov, 2013 US8613949
Dispatch to FDC 22 Nov, 2013 US8613949
Issue Fee Payment Received 20 Nov, 2013 US8613949
Issue Fee Payment Verified 20 Nov, 2013 US8613949


Aliskiren Hemifumarate; Amlodipine Besylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List